Evidence map›Paper›PMID 20164854›Full record

ArticleLeukemia2010

KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.

S Medves, F P Duhoux, A Ferrant, F Toffalini, G Ameye, J-M Libouton, H A Poirel, J-B Demoulin

Abstract readCase ReportsLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Targeting the PDGF signaling pathway in tumor treatment.Cell communication and signaling : CCS · 2013
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

S Medves
F P Duhoux
A Ferrant
F Toffalini
G Ameye
J-M Libouton
H A Poirel
J-B Demoulin
Cliniques Universitaires Saint-Luc · BEde Duve Institute · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adaptor Proteins, Signal TransducingAgedAntineoplastic AgentsBenzamidesChromosomes, Human, Pair 5Chromosomes, Human, Pair 9Cytoskeletal ProteinsHumansImatinib MesylateIn Situ Hybridization, FluorescenceMaleMyeloproliferative DisordersOncogene Proteins, FusionPiperazinesPyrimidinesReceptor, Platelet-Derived Growth Factor betaAdaptor Proteins, Signal TransducingAntineoplastic AgentsBenzamidesCytoskeletal ProteinsImatinib MesylateKANK1 protein, humanOncogene Proteins, FusionPiperazinesPyrimidinesReceptor, Platelet-Derived Growth Factor betaTumor Suppressor Proteins

Identifiers

PMID20164854
OpenAlexW2095197902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.